Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK p.Gly1202Arg (p.G1202R) ALK p.Gly1202Arg (p.G1202R)
- Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse. Biopsy was taken within half a month and total DNA was extracted from the sample. Exons 20-28, which correspond to the tyrosine kinase domain of ALK, were sequenced, and ALK G1202A was found. CKIT focal amplification by FISH was also observed. Tumor sample before crizotinib treatment was not available in this case.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1357
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/171
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Crizotinib
- Evidence Level
- C
- Clinical Significance
- Resistance
- Pubmed
- 22277784
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Resitance or Non-Reponse | true |